Saatvik Green Energy Q2 FY27: consolidated PAT falls 76% YoY to ₹20 Cr as margins compress
PAT -75.68% YoY · revenue +17.54% · margins compressing
₹902.71 Cr
+17.54% YoY
₹20.25 Cr
-75.68% YoY
2.18%
-8.5pp YoY
₹1.64
Saatvik Green Energy's consolidated (primary) PAT fell 75.7% YoY to ₹20.25 Cr (from ₹83.24 Cr) even as revenue grew 17.5% YoY to ₹902.70 Cr, pushing net margin down to 2.24% from 10.63% a year ago. Sequentially PAT jumped 277% QoQ and revenue 76.7% QoQ, but that is a recovery off Q1 FY27's unusually weak ₹5.36 Cr PAT base, not a trend reversal — YoY is the real signal here and it is still a profit decline. A ₹2.63 Cr exceptional charge for fire damage to plant and inventory at a subsidiary's Ambala facility sits in the consolidated P&L (insurance claim filed but recovery not yet booked); stripping it out, adjusted PAT still falls ~73.4% YoY, barely different from the 75.7% reported figure, so the one-off is not the real story — underlying margin compression is. The squeeze shows up mainly in cost of materials and purchases of stock-in-trade, which together absorbed essentially all of the revenue gain, consistent with a business still running on EPC/module-trading economics ahead of its own cell-integration ramp.
Q2 FY-2027 vs prior quarters
Against management's own FY27 guidance (₹6,000 Cr revenue, 12% EBITDA margin, 6-7% PAT margin, cell ramp from Q3 to ~80% utilization by Q4), the quarter reads as a miss-in-progress: H1 FY27 consolidated revenue of ₹1,413.8 Cr covers only ~23.6% of the full-year target, and H1 blended NPM of ~1.9% is well short of the 6-7% full-year PAT margin goal, though the company has explicitly front-loaded the margin improvement to H2 as cell capacity comes online. No analyst consensus or brokerage preview specific to this quarter's PAT turned up in search, so vsStreet is unknown; the closest reference point is Ambit's FY27 topline growth estimate of ~29.7% YoY and a Street revenue consensus near ₹6,300 Cr for FY27, both roughly in line with management's own number rather than offering an independent read on this quarter's profit miss. This is also the second straight quarter of steep YoY profit decline — Q1 FY27 PAT had plunged ~95% YoY — so the cautious tone from the prior concall (bearish sentiment, cautious management tone) has been borne out rather than reversed.
The stock went into the print at ₹349.8, down 12.8% over the past month of trading.
FY27: 3.5–4 GW sales, ₹6,000 Cr revenue, 12% EBITDA, 6–7% PAT margin. Capex ~₹3,500 Cr for Phase 1+2 (2.4 GW cell + 4 GW module + 3.6 GW cell). Cell ramp starts Q3, expected 80% utilization by Q4.
— This quarter: missed
Operationally, the quarter saw continued order momentum: a ₹1,041.63 Cr SECI order (Sep 16) and a ₹100 Cr MSEDCL order (Oct 10) add roughly ₹1,142 Cr to the book, alongside a new high-efficiency module launch (Oct 22) and a subsidiary starting solar PV module production just after quarter-end (Nov 2) — the first concrete step toward the guided capacity ramp. No management press release or concall commentary accompanied this specific filing (only the regulatory outcome letter), so there is no company framing to reconcile against the numbers this quarter. Standalone (secondary) results — ₹290.3 Cr revenue, ₹13.54 Cr PAT, EPS ₹1.07 — are structurally smaller than consolidated since the manufacturing subsidiaries, not the standalone EPC/holding entity, carry the bulk of revenue and the exceptional fire charge. The quarter sets up Q3-Q4 as the real test of the FY27 guidance: cell utilization ramping toward 80% by Q4 needs to show up in both revenue scale and the margin line for the 6-7% PAT margin target to still be credible.
W1
Cell capacity ramp from Q3 FY27 toward ~80% utilization by Q4 FY27, per management's own guidance — watch for confirmation in Q3/Q4 volumes and revenue.
W2
FY27 PAT margin guidance of 6-7% versus H1 FY27 blended NPM of ~1.9% — needs a sharp H2 margin inflection to be met.
W3
Resolution of the ₹2.634 Cr fire-damage insurance claim at the subsidiary facility — currently unrecognized, a settlement could add a one-time recovery in a future quarter.
Filing states 'all amounts in INR millions' — divided by 10 for ₹Cr; consolidated PBT carries a ₹2.634 Cr exceptional loss from a fire at a subsidiary's Ambala plant (insurance claim lodged, not yet recognized as recoverable) — standalone has no exceptional item; both statements tie out exactly to the reported subtotals.
Revenue surges 17%, profit collapses 76%; cell ramp leaves margins in Q3
Saatvik delivered ₹902.6 Cr in Q2 revenue (+17.5% YoY), but net profit plunged 75.7% as margins compressed to 2.2% from guided 6-7%. Cell Phase 1 commissioned on schedule, but accretion benefit now deferred to Q3+, and FY27 ₹6,000 Cr revenue guidance is mathematically implausible.
₹902.6 Cr
+17.5% YoY, +76.6% QoQ
₹20.2 Cr
-75.7% YoY despite revenue growth
2.2%
vs 6-7% guidance; -350 to -450 bps miss
58.5%
Q2 modules; below required 70%+
On the surface, Saatvik's Q2 looks like a growth story — revenue climbed 17% year-on-year and surged 77% quarter-on-quarter. But the profit line tells a different story. Net profit fell 76% in a quarter of rising sales, a gap that reveals the real tension: margin compression has completely offset volume growth. This isn't about demand — it's about a company caught between two eras: the old module-led business running at fractional margins, and a cell-integrated future that hasn't yet kicked in.
Why profit fell despite rising revenue
The PAT margin fell to 2.2% in Q2 from 6-7% in the prior-year quarter and from management's FY27 guidance of 6-7%. EBITDA margin stands at 7.7% against a 12% target. The culprits, per the CFO: commodity pricing volatility and forex headwinds. Module segment remains 96% of sales, and at commodity-like DCR utility pricing (₹20/Wp), there's no margin cushion. Non-DCR orders fetch ₹12-13/Wp — higher margin but lower volume. The integrated cell manufacturing benefit — central to management's pitch — is not yet flowing through. Cell Phase 1 (2.4 GW) is live and undergoing ALMM inspection, but accretion to margins is now expected only from Q3 onwards, not Q2.
Q2 execution caught up with order book demand
OverstatedSales 640 MW in Q2; order book 6.68 GW = 10+ quarters of supply. Capacity utilization only 58.5% suggests customer delays or demand softness, not catch-up.
Cell manufacturing ramp will drive 12% EBITDA margins in FY27
ContradictedQ2 EBITDA margin 7.7%; PAT margin 2.2% vs 6-7% guided. Cell Phase 1 commissioned but accretion deferred to Q3+. ALMM inspection pending — no benefit in Q2.
FY27 ₹6,000 Cr revenue target remains on track
ContradictedH1 FY27 delivered ₹1,413.6 Cr (23.6% of annual target). H2 would need ₹4,586.4 Cr — a 3.24x acceleration from H1 run-rate. At current 640 MW/qtr sales, mathematically implausible.
Odisha Phase 1 (1.3 GW modules) operational mid-November 2026
SupportedPhase 1 modules commissioned November 2, 2026. Production ramp to full capacity targeted December. Cell 2.4 GW ALMM inspection within 2-3 weeks post-Diwali.
What changed on this call
Phase 1 infrastructure is now live. The Odisha plant's 1.3 GW module capacity went operational in early November; cell and module manufacturing at the same location are expected to integrate by December. This is material — it marks the inflection from module-only to integrated manufacturing. But the margin accretion is now a Q3+ event. Management had previously signalled cell ramp benefits flowing through in Q2. That didn't happen. The ALMM (Approved List Methodology) inspection for the 2.4 GW cell line is now the gatekeeping event, scheduled within 2-3 weeks post-Diwali. If inspection passes on schedule, margin contribution begins in Q3 (partial) and Q4 (full), per management. If delayed, the timeline extends further. Capacity utilization sits at 58.5% — below the 70%+ required to hit FY27 guidance. This signals either customer delays (orders are queued at 6.68 GW but not yet converting to shipments at expected velocity) or softer demand than the headline order book suggests. Management framed Q2 as a 'realignment year' due to ALMM transition but offered no revised targets.
Strong 6.68 GW order book provides 10+ quarters of revenue visibility
Phase 1 Odisha plant commissioned on schedule; integration path clear
Long-term integrated manufacturing strategy (ingot → wafer → cell → module) is sound and capital-backed
PAT margin collapsed 75.7% YoY despite revenue growth; FY27 guidance credibility now in doubt
Capacity utilization 58.5% signals demand may be softer than order book suggests
ALMM inspection risk: if cell inspection is delayed, margin accretion pushed to Q4 or beyond
Module pricing power remains weak; utility segment (52% of revenue) locked in commodity-like DCR margins
FY27 revenue guidance is mathematically implausible
HighIf target is revised downward (from ₹6,000 Cr to ~₹4,200 Cr implied by H1 + modest H2 acceleration), management credibility erodes. Multiple compression risk.
ALMM cell inspection timing slips beyond 2-3 weeks
HighMargin accretion from cell ramp is the story management sold. If inspection delays, margins stay compressed in Q3, pushing recovery to Q4 or FY28. Stock vulnerable to each delay news.
Capacity utilization stays <70% through Q3
HighCurrent 58.5% utilization flags demand softness. If not fixed, integrated model economics don't work. Module pricing spiral risk in a supply-surplus market.
China export controls (Section 232 / Dec 4, 2026) disrupt long-term wafer supply contracts
MediumSaatvik sources tier-1 China wafer; Phase 3 ingot/wafer (FY29) is not on stream yet. Tech/supply constraints could force price hikes or delays.
Commodity pricing volatility continues; no pricing power with utility customers
MediumCFO cited forex and commodity swings for margin miss. With 52% utility revenue locked at DCR rates, margin sensitivity to raw materials is high. Hedge or diversify needed.
How the street is positioned
Post-result price action — no pop, persistent weakness. The stock opened the result period at ₹359.1 on 2026-11-11 (report date), below all major moving averages (SMA20 ₹366.49, SMA50 ₹395.04, SMA200 ₹419.37). RSI sits at 41.8 (neutral momentum). The lack of a post-result rally is telling — the market read the margin miss and the guidance gap the same way an analyst does. The stock remains down 36.67% from its all-time high of ₹567, and off the 52-week low of ₹328 by just 9.48%. The momentum is bearish, not because the stock is cheap, but because execution is now in doubt. Valuation drawdown context. At ₹359.1, Saatvik sits at a 35% discount to its ATH on the back of three quarters of strategic execution (Phase 1 commissioned, cell ramp underway) that has *not yet paid off*. A drawdown this steep usually signals either a repricing of long-term value (justified if the integrated thesis stalls) or an opportunity (if ALMM clears and utilization rebounds). The market has chosen the former — it's betting the thesis doesn't work at these margins and utilization levels. That's a risk you can't ignore. Foreign investors are exiting; domestic holding steady. Foreign institutional ownership has collapsed from 0.46% in Q2 FY26 to just 0.19% as of Q1 FY27 — a 60% trim in FII exposure. Domestic institutional ownership remains stable at 10.97%, and promoters stay locked at 75.99% (unchanged all year). The FII exit is significant: it signals that global capital is uncomfortable with execution risk and guidance credibility at current levels. Domestic institutions have not followed — yet. That's a divergence worth watching.
1 · ALMM cell inspection outcome (within 2-3 weeks post-Diwali)
This is the gate. If inspection passes and production ramp proceeds on schedule, Q3 will show the first margin contribution from cell manufacturing. Stock could re-rate 10-15% on clear. If delayed, margin accretion pushes to Q4 or FY28 — near-term pain continues.
2 · Q3 FY27 capacity utilization (December 2026 onwards)
Management targets 70%+ utilization to hit margin guidance. Watch whether Phase 1 ramp accelerates order conversion or whether customer delays persist. Utilization >70% + cell integration = confidence recovery. <65% = demand problem.
3 · FY27 revenue guidance revision or restatement
If management quietly revises FY27 from ₹6,000 Cr downward (to ₹4,200-4,500 Cr implied), credibility gap widens — stock could lose another 10-15%. If they reiterate, watch actual H2 sales velocity closely. If it accelerates 2x from H1, thesis may still work. If it stays flat, guidance is toast and management loses analyst support.
Saatvik is not a broken story — Phase 1 is live, order book is real, and the integrated manufacturing thesis is sound. But execution has lagged capital deployment, and FY27 guidance is implausible. This quarter is not a 'hold through; it's a 'pause and watch for catalysts.' PAT margin of 2.2% vs 6-7% guidance is a massive miss; it won't be solved by Q3 unless cell accretion is immediate and utilization jumps. The stock's 35% drawdown from ATH reflects that doubt. Wait for ALMM clearance and utilization inflection before adding. The number to track from here is Q3 capacity utilization — if it's still below 65%, the demand problem is real and the integrated thesis hits a wall. If it's >70%, the risk reward turns.
Growth masked by 76% PAT collapse; margin ramp now Q3+ dependent
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Missed margin guidance by ~350-450 bps. FY27 ₹6,000 Cr revenue target appears unachievable at current sales velocity.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Saatvik is executing on integrated manufacturing strategy with Phase 1 cell commissioned and strong 6.68 GW order book. But Q2 PAT margin of 2.2% vs guided 6-7% is a massive miss; at current run-rate, FY27 ₹6,000 Cr revenue target is unachievable (H1 is only ₹1,413.6 Cr). Regulatory (ALMM), commodity, and capacity-utilization headwinds must clear before re-rating.
₹902.6 Cr
Revenue · +17.5% YoY₹20.2 Cr
Reported PAT · −75.7% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Q2 execution caught up with order book
OVERSTATEDSales 640 MW, order book 6.68 GW = 10+ quarter supply; capacity utilization 58.5% signals demand softness
Cell manufacturing ramp underpinning margins by 12% EBITDA FY27
MISSQ2 EBITDA margin only 7.7%; PAT margin 2.2% vs 6-7% guidance; cell at trial stage, ALMM inspection pending
FY27 ₹6,000 Cr revenue target on track
MISSH1 ₹1,413.6 Cr implies H2 needs ₹4,586 Cr (3.24x H1 run-rate); unrealistic at 640 MW/qtr sales
Odisha Phase 1 (1.3 GW modules) operational mid-Nov 2026
MET1.3 GW module capacity commissioned ~2 Nov; ramp production by Dec 2026 still ahead
Earnings quality
What changed since the last call
FY27 revenue guidance re-stated but credibility weakened
NeutralMaintained ₹6,000 Cr target but H1 delivery of ₹1,413.6 Cr (23.6% of annual) implies H2 must deliver ₹4,586 Cr (3.24x H1), implausible at 640 MW/qtr sales.
Margin guidance credibility collapsed
DowngradeQ2 EBITDA margin 7.7% vs guided 12%; PAT margin 2.2% vs guided 6-7%. Cell ramp deferred from Q2 to Q3+ entry point.
Order book re-validated as strong strategic underpinning
Neutral6.68 GW order book (110% of module capacity) vs 6.35 GW at Q1, but sales velocity (640 MW/qtr) shows single-digit % utilization.
The Q&A
Analysts pressed on margin recovery (commodity vs operational), cell ramp timing, and FY27 revenue achievability. Management hedged on margin percentages, blamed ALMM transition and commodity cycles, and offered no revised target. Tone cautious, not defensive; CFO deflected utilization targets as 'realignment year'.
Revenue realization by segment — Abhishek, Motilal Oswal
AnsweredDCR ~₹20/Wp, non-DCR ₹12-13/Wp. Utility segment majority at 52-55%, retail 12%, C&I 28%, export 3%.
China export controls impact — Abhishek, Motilal Oswal
PartialMonitoring closely; tech already moved outside China in other countries. Phase 1 ready, Phase 2 tie-up also secure. Not worried but watching 15 Nov announcement.
SuryaConnect B2C kit competitive positioning — Jainam Jain, IIFL Capital
AnsweredB2C model through distribution dealers (85-90 across India), turnkey for IEC-registered installers. Already ~57k homes in pipeline; 140 competitors but brand equity differentiator. Targeting 15% of revenue in 2 years.
Module vs cell/ingot/wafer capacity and margin contribution — Myra Mittal, Individual Investor
AnsweredEPC/pumps/inverters/batteries contributed ₹408 Cr H1 revenue (4% of total, targeting 15%). Panels 50-60% project cost, inverters 10%, transformers >10%. Want to increase share to 70-80% in solar projects.
Odisha Phase 1 commissioning and margin accretion timeline — Mahesh Kumar, MU Investment
Partial1.3 GW modules operational early Nov; cell 2.4 GW trial complete, ALMM inspection within 2-3 weeks post-Diwali. Margin benefit Q3 partial, full Q4 onwards. Ramp to 97-98% yield by year-end.
FY27 revenue guidance validation and H2 implied growth — Abhishek, Motilal Oswal
DodgedFY27 guidance (though said FY28 initially, then corrected). H1 ~₹1,413.6 Cr confirms trajectory; with cell commissioning, expecting 15-17% growth in second half.
Wafer sourcing and ALMM List-III ingot/wafer capacity — Nimish Pandya, NP Investments
AnsweredAlready ramping cells with tier-1 China suppliers long-term contracts. Phase 3 ingot (6 GW) + wafer (6 GW) in Odisha by FY29. ALMM List-III kicks June 2028; aligned with policy. Domestic capacity still only ~37 GW vs 200+ GW module capacity.
Module capacity utilization and pricing pressure forecast — Abhishek, Motilal Oswal
DodgedForward-looking; hard to predict. This year is realignment with ALMM and commodity swings. Next fiscal smoother with 80% module utilization target. Margin peer-referenced; should be 'close proximity' but withheld exact numbers.
Guidance
FY27 ₹6,000 Cr with 12% EBITDA margin
LowH1 ₹1,413.6 Cr (23.6% of annual); H2 needs ₹4,586 Cr (3.24x H1 run-rate). At 640 MW/qtr sales, target unachievable.
FY27 12% EBITDA, 6-7% PAT margin
LowQ2 EBITDA 7.7%, PAT 2.2%; H1 EBITDA 7.9%. Cell ramp benefit now deferred from Q2 to Q3+ due to ALMM inspection delay.
~₹3,500 Cr for Phase 1+2 (2.4 GW cell + 4 GW module + 3.6 GW encapsulant)
HighPhase 1 Odisha operational Nov; Phase 2 (3.6 GW cell, 27 acres) targeted FY28. Phase 3 (ingot/wafer) FY29.
Risks the call surfaced
Regulatory / ALMM compliance
HighCell 2.4 GW ALMM inspection pending within 2-3 weeks post-Diwali. If delayed or failed, margin accretion deferred to Q4 or FY28. Ingot/wafer ALMM List-III kicks June 2028.
Execution / capacity ramp
HighPhase 1 (1.3 GW modules) commissioned Nov 2, 2026; full 4 GW module + 2.4 GW cell by Dec 2026. Capacity utilization only 58.5% Q2, suggesting demand/market softness. If utilization remains <70%, margin targets unachievable.
Commodity / cost inflation
HighCFO blamed commodity and forex swings for Q2 margin compression (PAT -75.7% YoY). No firm pricing power with utility/large customers; non-DCR smaller customers better margin but lower volume.
Guidance credibility / FY27 revenue miss
HighH1 ₹1,413.6 Cr (23.6% of annual target); H2 needs ₹4,586 Cr (3.24x H1 rate). At 640 MW/qtr sales, this is mathematically impossible unless order execution 3x-4x accelerates.
Competitive positioning
MediumIndustry shifting from module-led to cell-led integrated model. Saatvik still majority module revenue (96% H1); cell/ingot/wafer integration not yet accretive. Competitors with earlier cell ramp (REC Solar, Adani Green) may gain market share.
Management
Score 6/10. Clear on strategy and capacity expansion roadmap but evasive on margin recovery timeline and FY27 revenue achievability. CFO used 'realignment year' framing to deflect miss. Cell Phase 1 (1.3 GW) commissioned on schedule; module ramp underway. But PAT -75.7% YoY and margin target miss by 350-450 bps shows disconnect between strategic narrative and operational reality.
1 · Nov-Dec 2026
Cell 2.4 GW ALMM inspection completion; full 4 GW module ramp to operational capacity
2 · Dec 2026
Odisha Phase 1 production ramp to 4 GW module + 2.4 GW cell full capacity utilization
3 · Q3 FY27
Cell manufacturing margin benefits expected to flow through as ALMM ramp increases integrated offerings
Regulatory (ALMM), commodity, and capacity-utilization headwinds must clear before re-rating.